ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s share price dropped 8.1% on Thursday . The stock traded as low as $3.55 and last traded at $3.59. Approximately 5,056,670 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 6,274,826 shares. The stock had previously closed at $3.90.
Analyst Ratings Changes
Several brokerages have commented on IBRX. BTIG Research assumed coverage on shares of ImmunityBio in a research report on Friday, January 10th. They issued a "buy" rating and a $6.00 price target on the stock. D. Boral Capital restated a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a report on Friday, February 14th.
Get Our Latest Research Report on IBRX
ImmunityBio Price Performance
The firm's fifty day simple moving average is $2.99 and its 200 day simple moving average is $3.79. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -3.72 and a beta of 0.94.
Institutional Trading of ImmunityBio
A number of hedge funds have recently modified their holdings of IBRX. Courier Capital LLC boosted its position in ImmunityBio by 50.0% during the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company's stock worth $112,000 after acquiring an additional 10,000 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after buying an additional 4,545 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in ImmunityBio by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 133,966 shares of the company's stock worth $498,000 after buying an additional 52,716 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of ImmunityBio by 290.3% during the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company's stock valued at $402,000 after buying an additional 80,318 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of ImmunityBio during the 3rd quarter valued at $253,000. Hedge funds and other institutional investors own 8.58% of the company's stock.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Recommended Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
